Considering the near-term challenges, we maintain our HOLD rating on the stock and revise our TP to Rs 320/share. The TP implies an upside potential of 3% from the CMP.

GCPL is set for a stronger H2FY26 with recovery in Personal Wash post-GST cut and continued momentum in Household Insecticides and Hair Colour.

P&G Hygiene and Healthcare’s (PGHH) 2QFY26 revenue growth was broadly in line with our expectations, but profitability was a miss. Similar margin anomalies have been observed in past quarters.

Dabur India reported another quarter of too many moving parts, with the outlook likely to get better in the near term. The fact that it gained market share in 95% of its portfolio indicates market growth (also) is to be blamed for the unexciting Q2FY26 revenue print.

Management expects a gradual demand recovery in H2FY26E, supported by improving macro indicators and internal execution initiatives.

With a 6% upside from the CMP, we maintain our HOLD rating on the stock.

About the stock: Hindustan Unilever (HUL) is India's largest FMCG company with presence of more than 90 years. The company has portfolio of 50+ brands spanning to various categories such as detergents, personal wash and skin care & colour cosmetics. 80% of revenues come from products having leadership positioning in...

We expect the Company to outperform in H1FY26E over H2FY25, led by stronger volume offtake aided by continued transformation in the and on the back of improving macro tailwinds.

We have revised our FY26E/FY27E EPS estimates by -5.7%/-1.9%, as we factor in weaker EBITDA margins led by contraction in gross margins. We reiterate our “ACCUMULATE” rating on the stock, supported by its volume-led growth strategy. We expect margin pressure to remain persistent in the near term
but expect gradual recovery from H2FY26E onwards

Considering the near-term challenges, we have downgraded the stock from BUY to HOLD and revised our TP to Rs 355/share, implying an upside potential of 7% from the CMP.

MRCO delivered 22% revenue growth along with ~9% volume growth led by prices hikes taken in Parachute, robust growth in Foods and Premium Personal Care along with sustained recovery in VAHO. IBD continues to grow strong...

With an upside potential of 6% from the CMP, we maintain our HOLD rating on the stock

With a 7% upside from the CMP, we maintain our HOLD rating on the stock

Colgate Palmolive India’s Q1FY26 performance stood below our expectations across the board, reflecting persistent headwinds from tough operating conditions led by muted urban demand and elevated competition intensity.

We cut FY26/27 EPS by 7.1/7.4% given subdued urban demand, competitive pressures and little scope to increase margins from current elevated levels. CLGT 1Q26 was a miss on estimates with 4.4% revenue decline led by 2.8% volume decline (high base, subdued urban demand and intensifying competitive pressures). Near term outlook remains cautious as impact of high base, tepid urban demand, heightened competition and promotions/...

PGHH’s strategic pillars that drive growth in the Personal and Healthcare categories are intact. The company holds a dominant ~50% market share in both the Feminine Hygiene and Healthcare categories.

Cautious outlook for 1H26 due to muted urban demand, expect recovery led by innovations & rural momentum post 2Q. increased promotional spending led by heightened competitive intensity. Near term outlook is cautious given that 1) urban demand continues to remain muted at mass end 2) heightened competitive landscape 3) rising promotional...

The company reported robust revenue growth during the quarter on account of higher volume. However, margin and profitability were impacted by the higher cost of sales. Marico expects better outlook as its Food portfolio is expected to grow by 25% in FY26 owing to its scaling up of existing franchises and product innovations. Volume is expected to be better in FY26 as compared to FY25, indicating a favourable performance in the future. Its strong market share and new businesses...

FY26 growth acceleration depends on repositioned Smart & Handsome, brightening cream response, Kesh King strategy and revival in Man company HMN delivered 6.5% revenue growth in FY25 led by healthy volume & pricing growth. Navratna, Dermicool, Boro Plus, and Healthcare drove robust performance while Male Grooming, Kesh King, and Strategic Subsidiaries dragged overall growth. The Man Company & Brillare will see some pick-up in FY26 led by increasing share on quick commerce platforms and 360-degree...